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Hepatocellular Carcinoma and 




The development of direct-acting antiviral (DAA) therapies in chronic HCV 
infection has been associated with increased expectations regarding the prognosis 
of this infection in the medical community, as the possibility of HCV eradication 
is now in sight. While the cure of the HVC infection has been associated with a 
dramatic decrease in its systemic complications, the impact on the progression 
of the liver disease, especially in patients with cirrhosis, is still controversial. 
Furthermore, the risk of developing hepatocellular carcinoma (HCC) after 
direct-acting antiviral therapy is debatable, with studies presenting an increased 
prevalence of HCC early after the introduction of these therapies, as well as newer 
contradicting studies. This chapter aims to examine the current literature data 
available regarding the impact of new HCV therapies in the incidence and prog-
nosis of hepatocellular carcinoma.
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1. Introduction
Hepatitis C virus (HCV) chronic infection is one of the leading causes of 
morbidity and mortality, with over 71 million people infected worldwide. [1] Its 
natural evolution comprises liver cirrhosis and its complications, including hepa-
tocellular carcinoma (HCC). HCV infection is the leading factor associated with 
HCC in Western European countries and USA, with an increased risk of up to 20 
times greater than the general population. [2] The association between HCC and 
HCV occurs in cirrhotic patients; an estimated 20% of patients with HCV chronic 
infection develop cirrhosis within 20–30 years of infection, and, of those, 1–4% 
develop HCC each year. [3] The risk of developing HCC in the course of HCV 
infection is related not only to the presence of the virus, but also to viral genotype, 
concurrent liver disease or metabolic syndrome (diabetes mellitus, obesity) and 
lifestyle factors. [4]
HCV genotypes 3 and 6 are associated with higher HCC risks [5, 6]. 
Furthermore, co-infection with hepatitis B virus (HBV) or human immunodefi-
ciency virus (HIV) doubles the risk of developing HCC in younger HCV infected 
patients. [7] Smoking and alcohol abuse are associated with an increased risk of 
HCC in HCV infected patients as follows: a relative risk of HCC of 23 in smoking 
patients, as opposed to 7.7 in non-smokers [8] and a 2 fold increase in the risk of 
HCC in patients with an alcohol intake over 60 g daily. [9] On the other hand, 
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coffee-drinking has beneficial effects on both the progression of liver disease and 
the HCC development. [10]
Diabetes mellitus is an important cofactor in the development of HCC associated 
with the HCV infection. On the one hand, the presence of HCV is an important risk 
factor for the development of type 2 diabetes. [11] HCV has a direct action against 
beta-pancreatic cells [12] and also a systemic pro-inflammatory action, inducing the 
expression of TNF-α and IL-6 which promote insulin-resistance. [13] On the other 
hand, the development of diabetes is associated with an increased risk of HCC of up 
to 3 fold, due to insulin resistance, increased inflammation, inhibition of apoptosis 
and the generation of pro-oncogenic mutations. [14] Obesity is also a risk factor 
for the development of HCC, due to increased production of pro-inflammatory 
cytokines and insulin resistance which mediate carcinogenesis.
2. Relationship between HCV and HCC
There are two main mechanisms of carcinogenesis in HCV chronic infection: the 
carcinogenetic hepatic environment produced by the HCV infection per se and the 
direct carcinogenetic effect of several HCV proteins, both structural (core, E1, E2) 
and non-structural (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B). [15]
Experimental studies have revealed the impact of the viral protein expressions 
on cellular proliferation. For example, over-expression of core proteins, NS3, NS5A 
promotes cellular proliferation and tumor transformation in mice, via oncogenic 
molecular pathways. [16, 17] The core protein also inhibits tumor suppressor genes 
(TP53 TP73) and negative regulation factors of the cell cycle. [18] Aggressive phe-
notypes of HCC are associated with the activation of cellular proliferative pathways 
(RAF/MAPK/ERK kinase) by the HCV core protein as well as by NS5A and NS5B. 
[19] Furthermore, HCV core protein stimulates the production of oxygen reactive 
species, with an important role in the pathogenesis of HCC, and also inhibits the 
tumor suppression activity of TGF- beta. [20, 21] NS5A protein inhibits caspase-3 
enzyme (thus stimulating evasion from apoptosis) and prevents nuclear transloca-
tion of Smad proteins, inhibiting TGF beta signaling with the final outcome of 
down-regulating tumor suppressor cyclin-dependent kinase inhibitor 1. [22, 23] 
NS5A also induces chromosomal instability and mitotic dysregulation as well as 
apoptosis mediated by TNF-alpha. [24, 25]
Alterations of the host genomic DNA are described in HCV infection (oncogenic 
mutations, deletion of tumor suppressor genes), with an important impact on 
HCC carcinogenesis. The core protein inhibits mitotic spindle checkpoint function, 
increases chromosomal polyploidy, while the chronic oxidative stress induces mito-
chondrial and chromosomal DNA alterations. [20, 26]. HCV induces endoplasmic 
reticulum perturbations and prolonged stress, which leads to accumulation of DNA 
mutations and a predisposition to carcinogenesis. [27]
Chronic inflammation also plays a part in HCC development. In support of the 
inflammatory model of carcinogenesis, it has been shown that inhibition of cyclooxy-
genase 2 prevents HCC in experimental models. [28] The core protein of HCV inhibits 
immune responses mediated by the nuclear factor kappa-B (NF- kB), involved in 
the progression of initiated tumor clones. [29] Extracellular core protein may inhibit 
antigen-presenting cells via the IL-6 pathway. [30] NS5A interacts with TNF receptor-
associated factor 2 and activates the JNK pathway (c-Jun N terminal kinase) generat-
ing an inflammatory environment in the liver that is the basis for HCC carcinogenesis. 
[31] Other viral proteins also affect immune mechanisms and promote carcinogen-
esis; for instance, NS3 has an immune suppressive effect by cleavage of mitochondrial 
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antiviral signaling proteins and E2 viral protein contributes to immune evasion by 
inhibiting natural killer cells. [32, 33]
HCV is an important factor in the dysregulation of normal liver metabolism and 
a promoter of steatosis. [34] It has been shown, in experimental animal models, 
that the expression of HCV core protein is associated with progressive steatosis and 
HCC, as well as insulin resistance and suppression of the assembly and secretion of 
very low density lipoproteins. [35–37] HCV core protein modulates cell differentia-
tion and proliferation, accentuates steatosis and oxidative stress via peroxisome 
activated receptor alpha. [38]
Normal hepatocellular senescence is also impaired in HCV infected patients. In 
the stage of cirrhosis, after regeneration cycles, cellular senescence is stimulated 
by telomere shortening, which decreases hepatocyte proliferation and prevents 
carcinogenesis. [39] In the HCV infection, hepatocyte senescence is inhibited and 
somatic mutations of the telomerase reverse-transcriptase promoter stimulate 
carcinogenesis. [40]
Fibrosis is the most important background in the development of hepatocellular 
carcinoma, as it stimulates genetic aberrations. [41] There is a direct correlation 
between the degree of liver fibrosis and the increased risk of HCV associated HCC 
in some patients, which may persist despite obtaining sustained virologic response 
by antiviral treatments, as there is still progression of liver fibrosis and its associ-
ated HCC risk. [42, 43] HCV core and other non- structural proteins stimulate 
profibrogenic, mitogenic and pro-inflammatory cytokines (TGF-beta, platelet-
derived growth factor, IL-8, Il-32). [15] In addition, HCV infected apoptotic cells 
may amplify fibrogenic signals. [44] Portal hypertension secondary to liver cir-
rhosis increases gut mucosa permeability and bacterial translocation, resulting in 
increased circulatory bacterial lipopolysaccharides, an important stimuli of fibro-
genesis and carcinogenesis. [45] The interaction between the HCV protein E2 and 
CD81 (pertaining to the complex responsible for HCV internalization) stimulates 
an inflammatory response resulting in liver damage. [46] Experimental studies have 
suggested the role of renin-angiotensin system in carcinogenesis, as administra-
tion of angiotensin-converting enzymes inhibitors inhibits angiogenic factors and 
decreases insulin-resistance related carcinogenesis. [47]
Different host-specific mechanisms have been incriminated in the development 
of HCV associated HCC. For example, is has been demonstrated that the epidermal 
growth factor (EGF) pathway is activated in hepatic stellate cells, stimulating cel-
lular growth, proliferation, differentiation and carcinogenesis, and its inhibition via 
EGF receptor inhibitor, erlotinib, diminishes fibrosis and reduces the risk of HCC. 
[48] In other trials, erlotinib has proven effective in preventing HCV infection, by 
inhibiting HCV cellular entry. [49] In addition, gefitinib (another EGF inhibitor) 
has proven effective in experimental animal models in suppressing HCC growth 
in subjects with established HCC lesions. [50] Sorafenib, a multi-kinase inhibitor, 
inhibits angiogenesis and has beneficial roles in portal hypertension as well as HCC 
by blocking the response to vascular endothelial growth factor. [51] Host related 
factors predicting response to antiviral therapy appear to play a role in HCV associ-
ated HCC risk. Il28B variants CT or TT, used to predict virologic response to inter-
feron therapy, also increases the risk of developing HCC. [52] Molecules pertaining 
to the major histocompatibility complex class I are involved in fibrogenesis and 
carcinogenesis by inflammatory mechanisms. [53] Metabolic disturbances, such as 
those involved in the iron metabolism leading to hepatic iron overload, stimulate 
steatosis, mitochondrial alterations and carcinogenesis, especially in HCV-based 
models. [54] The presence of HCV infection dysregulates the activity of microRNAs 
in a distinct pattern. [55]
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3. Hepatocellular carcinoma in the setting of DAA treatments
Currently, the most important international panels recommend using direct 
acting antiviral (DAA) therapies for all degrees of liver fibrosis, customized for 
all HCV genotypes, with significant advantages: very high response rates (over 
90%), short treatment duration and few adverse effects [56–58] These options are 
summarized in Table 1.
Not only do all guidelines recommend antiviral treatment in chronic HCV infec-
tion regardless of degree of liver fibrosis or other comorbidities, but they also indicate 
that the presence of HCV associated comorbidities is a strong argument in favor of 
antiviral therapy. The use of DAA in patients with HCC is still under debate. The 
European guidelines recommend that HCV treatment in patients with HCC should be 
administered after curative (ablation, resection) or palliative procedures (transarte-
rial chemoembolisation). [59] The reasoning behind this recommendation is that 
patients with HCC have lower response rates to DAA. [60] A recent meta-analysis 
on over 5500 patients with HCC revealed a SVR rate of 88%, with higher rates 
reported in patients who received curative HCC treatment compared to those with 
non-curative therapies or not treated. [61] Furthermore, patients with HCC awaiting 
liver transplantation who received DAA had a lower risk of dropout caused by tumor 
progression or death. [62] Strong recommendations are made in favor of treating 
HCV associated HCC patients after liver transplantation. [63] In HCV patients with 
treated HCC, without indication for liver transplantation, the indication of DAA 
treatment is uncertain. Large cohort studies show that obtaining SVR is associated 
with lower risks of de novo HCC and liver-related mortality in the mid and long term. 
[64, 65] On the other hand, a large study has shown that the high HCC risks persist up 
to 10 years after SVR in patients with advanced fibrosis. [66] There is no clear conclu-
sion regarding the impact of DAA treatment on the risk of HCC recurrence following 
curative procedures, as shown by a review and meta-analysis on 13000 patients. [67] 
Another retrospective cohort study on 797 patients with HCV infection and a history 
of HCC with complete response to ablation, resection, transarterial chemo- or radio-
embolisation concluded that DAA therapy decreases the incidence of overall deaths. 
[68] A recent expert literature review states that DAA treatment decreases the risk of 
de novo HCC in patients with and without cirrhosis, while the presence of active HCC 
significantly decreases SVR rates. [69] There was no association between antiviral 
therapy and the baseline risk, aggressiveness, time of progression of HCC.











SOF sofosbuvir; VEL velpatasvir, GLE glecaprevir, PIB pibrentasvir VOX voxilaprevir, LDV ledipasvir, GZR 
grazoprevir, ERB elbasvir, OBV ombitasvir, PTV paritaprevir, r ritonavir, DSV dasabuvir.
Table 1. 
Direct acting antiviral agents currently in use (regimens marked with orange are not indicated in the respective 
genotypes.
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The guidelines presented by the American Association for the Study of Liver 
Diseases in 2019 recommend screening for HCC in patients with advanced fibrosis 
before any antiviral therapy and elaborate simple treatment strategies for non-
cirrhotic patients including diagnosis, pre-therapeutic evaluation and follow-up 
so as to be accessible to a broad range of health care professionals. [57] In patients 
with decompensated cirrhosis or cirrhosis complications, a case-based decision is 
required. [70] An interesting study presented in the APASL consensus statements 
and recommendations on treatment of hepatitis C shows that, in patients with 
compensate cirrhosis and HCC, DAA treatment (sofosbuvir and ribavirin) admin-
istered at least 4 weeks prior to liver transplantation reduced the risk of allograft 
recurrence by 50%. [71]
4. SOF/VEL
SOF/VEL is a pan-genotypic all oral treatment regimen, consisting of a NS5B 
polymerase inhibitor (sofosbuvir) and a NS5A inhibitor (velpatasvir). [72] In a 
real life study of over 2800 HCV infected patients, this regimen showed an effi-
cacy of 94.6% in the general population, with an SVR rate of 88,6% in cirrhotic 
patients. Notably the number of cirrhotic patients included was significantly low. 
[73] In a trial on 102 Japanese patients with decompensated cirrhosis, HCC was 
diagnosed in 3 patients after the completion of antiviral therapy with SOF/VEL 
(in days 1, 70 and 124 respectively). Four other patients had a history of HCC 
resolved for more than 2 years prior to therapy and did not experience recurrence. 
[74] Another prospective multicenter trial studied the efficacy of SOF/VEL in 
71 patients with decompensated cirrhosis; among those, 22 patients (31%) had a 
history of treated HCC (by resection, ablation, transarterial chemoembolization, 
chemotherapy, heavy ion therapy, proton therapy), during a timeframe rang-
ing from 2 months to 13 years prior to DAA treatment. None of the patients had 
evidence of active HCC at the initiation of DAA therapy; however, the maximum 
level of alpha-fetoprotein noted at initiation was over 2000 ng/ml. 90.9% of 
patients with a history of HCC obtained SVR (compared to 94.4% in the entire 
study population); 4 patients presented HCC recurrence; no de novo HCC cases 
were reported. [75] 16 patients in a large trial involving 729 Chinese patients 
infected with genotype 2 HCV were given SOF/VEL, among which one had a 
history of HCC; all the patients obtained SVR and there was no recurrence in the 
HCC patient.
5. SOF/VEL/VOX
This is a pan-genotypic regimen, containing a NS5B polymerase inhibitor 
(sofosbuvir), a NS5A inhibitor (velpatasvir) and a NS3/4A protease inhibitor (voxi-
laprevir), with over 90% SVR rates in treatment naïve patients but especially in 
DAA- experienced patients and hard-to-treat categories, for which this regimen is 
currently reserved. [76, 77] One adverse reactions report has been filed regarding a 
treatment experienced patient developing HCC after treatment with SOF/VEL/VOX. 
[78] Another case report considers the undiagnosed presence of HCC as the cause of 
non-response to antiviral therapy re-treatment in a patient with HCV genotype 1b. 
[79] A large multicenter clinical trial reports HCC (alongside the presence of  
cirrhosis) as the only cause of treatment resistance in 179 patients with various 




The combination between Glecaprevir (a NS3/4A protease inhibitor) and 
Pibrentasvir (a NS5A inhibitor) is another pan-genotypic antiviral option in 
patients without cirrhosis or with compensated cirrhosis. [81] It has shown response 
rates of up to 100% and a rate of discontinuation due to severe adverse events of 
0.7% in clinical trials (SURVEYOR-I and SURVEYOR-II, comprising 449 patients). 
[82] Furthermore, newer trials reveal excellent response rates with a lower duration 
of therapy (8 weeks instead of 12 weeks) even in patients with compensated cir-
rhosis, without the identification of post-baseline cases of HCC. [83] An interesting 
study performed in Japan (a country with one of the highest rates of HCV infection 
and HCC incidence) evaluates the cost-effectiveness of GLE/PIB compared to other 
DAAs. [84] This study revealed a lower lifetime risk of HCC in patients treated with 
GLE/PIB or SOF/LDV (3.66%) compared to EBV/GRZ (4.99%). However, in a study 
evaluating safety and efficacy of GLE/PIB in DAA experienced patients, which 
enrolled 177 subjects (17 with a history of HCC but no active disease 6 month prior 
to treatment initiation) one death from HCC was reported, occurring after the end 
of the treatment but before the SVR12 evaluation. This was a non- cirrhotic patient, 
without history or proof of HCC at baseline, diagnosed with advanced HCC shortly 
before the end of treatment. Virologic failure occurred in 17.7% of patients with a 
history of HCC. [85] A large real-life cohort study evaluated the efficacy of several 
antiviral regimens in patients with and without HCC in Taiwan. [86]. Among the 
1237 patients, 193 received GLE/PIB; 9 of them had a history of HCC and one had 
active disease. The study notes no differences regarding SVR in patients with or 
without HCC. The same conclusion was drawn in regard to OBV/PVT/r + DVS 
(5 patients with active HCC), SOF/LDV and ELB/GZR (each with one patient with 
active HCC).
7. SOF/LDV
This is one of the first used all oral regimens, combining the well-known sofos-
buvir (NS5B polymerase inhibitor) with an NS5A inhibitor (ledipasvir). It is one 
of the few therapeutic regimens suited for patients with decompensated cirrhosis. 
[87] In a real life observational trial, SOV/LDV demonstrated a rate of SVR of 86%, 
in patients with cirrhosis Child A, B or C and transplant recipients, with a signifi-
cant improvement in MELD score. Out of 200 patients, only one HCC was newly 
diagnosed, while out of 35 patients with a history of HCC, 17 developed recurrence, 
depending on the previous (curative or non-curative therapies). [88] A retrospec-
tive analysis evaluating 62,354 patients treated for HCV chronic infection, either by 
interferon, DAA (including SOV/LDV) or both, revealed that achievement of SVR 
is associated with a 61% reduction in the risk of HCC. A higher incidence of HCC 
was noted after DAA only therapy (compared to interferon alone or interferon and 
DAA) but, after evaluating risk factors for HCC, analysis showed that the presence 
of cirrhosis, impaired liver function and diabetes (more prevalent in the DAA sub-
group) were responsible for the differences. [89] Another trial comparing the HCC 
risk after DAA with the risk after interferon-based therapy (819 patients treated 
with DAA, 380 treated with SOV/LDV), found that 9/380 patients developed new 
HCCs. The patients were older and had Child A or Child B cirrhosis; most of them 
were interferon-experienced. [90] Notably, in the same cohort, out of 120 patients 
treated with OBV/ PTV/r + DSV, 3 patients developed HCC. Failure to achieve 
SVR was the strongest risk factor associated with de novo HCC. In contrast, in the 
historical cohort of patients treated with interferon 19/283 patients developed HCC; 
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11 patients had no signs of cirrhosis at the time of therapy. A prospective multicenter 
trial studied the risk of de novo HCC after DAA therapies, including 158 cirrhotic 
patients and 31 patients with advanced fibrosis receiving SOF/LDV. Newly diag-
nosed HCC was reported in 35/985 patients after 48 weeks of surveillance. [91] Risk 
factors for HCC included male gander, failure to obtain SVR, presence of cirrhosis 
and hepatocytolytic syndrome; DAA therapy was not associated with an increased 
risk of HCC. In another retrospective trial, 1082 HCV patients receiving DAA or 
interferon-based therapies were monitored for de novo HCC; during follow-up 
33% developed HCC. The patients received different antiviral therapies, among 
them: SOF/LVD 41 patients, GLE/PIB 49 patients, GZR/EBR 44 patients and OBV/
PTV/r + DSV 41 patients. None of the antiviral therapies represented risk factors 
for HCC. [92]
8. GZR/EBR
This treatment regimen contains an NS3/4A protease inhibitor (grazoprevir) 
and an NS5A inhibitor (elbasvir) and can only be used in patients with genotypes 
1 and 4 HCV infection, with SVR rates of 92–99% in patients with chronic hepa-
titis and compensated cirrhosis. [93] In a real life retrospective study, out of 149 
patients, 27 of with had a history of HCC, no new or recurrent cases of HCC were 
reported. [94] According to a recent model, in patients with chronic HCV infec-
tion and renal disease, the estimated incidence of HCC was 1,2% in the GZR/ EBR 
group, 21,64% in the no-treatment group and 8,9% in the interferon group. [95] 
Furthermore, in a prospective report on 40 hemodialysis patients with genotype 
1b infection, there was one documented case of HCC at week 4 of therapy. [96] A 
trial of 349 patients treated with DAA, including 45 patients with a history of HCC, 
found 15 cases of HCC recurrence and 3 cases of de novo HCC, after a median sur-
veillance of 22 months after DAA (for recurrent HCC) and 16 months (for de novo 
HCC). 2 cases of recurrence occurred in the 19 patients treated with GZR/EBR. The 
most important risk factor for recurrence was the previous HCC management. [97]
9. OBV/PTV/r + DSV
This is a genotype 1 specific DAA combination including an NS5A inhibitor 
(ombitasvir) an NS3/4A protease inhibitor (paritaprevir) and an NS5B polymerase 
inhibitor (dasabuvir), while ritonavir acts as a pharmacokinetic enhancer. [56] A 
prospective analysis on 24 patients with HCV associated compensated cirrhosis 
and history of HCC revealed a decrease in HCC recurrence rate, as well as sur-
vival without recurrence, when compared to a control group. Patients had been 
previously managed with resection, radiofrequency ablation, and trans-arterial 
chemoembolization, had a history of 6 month of disease free survival and were 
monitored by CT scan or MRI every 6 months. The SVR rate in the study group was 
87% (lower than that recorded in patients without HCC). [98] Another prospective 
study on 278 patients with HCV related advanced fibrosis (F3-F4), without HCC 
history, revealed 11 cases on newly diagnosed HCC (5 during antiviral therapy, 2 at 
the end of therpy and 4 at 3 months after the end of therapy). The overall incidence 
of HCC did not surpass the general incidence. Notably, patients presented an 
infiltrative type HCC, difficult to observe on abdominal ultrasonography or even 
CT scan, requiring MRI. [99] In a multicenter trial in Brazil, out of 222 patients 
with advanced fibrosis, one patient was diagnosed with HCC at the end of therapy, 
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A large real world cohort study of 941 patients including 131 patients with con-
comitant HCC (79 without viable tumors and 52 with viable tumors) evaluated 
safety and efficacy of OBV/PTV/r + DSV. There were no differences in SVR between 
patients with and without HCC; risk factors for no response were Child Pugh A 6 
and low serum albumin. One patient died during treatment due to HCC rupture. 
[101] On the other hand, one of the first studies of HCC recurrence in the setting 
of DAA therapy which was performed in 4 Spanish hospitals, revealed a recurrence 
rate of 27.6% (16/58 patients); notably, initial evaluations showed no active disease 
for more than 6 months prior to DAA therapy. One of the 15 patients treated with 
OBV/PTV/r + DSV developed “non-characterized” nodules on liver imaging. [102]
10. Conclusion
The benefits of DAA therapy in patients with HCC have been proven by a 
propensity-matched trial on 1239 patients, with HCC managed by curative options 
or palliation. The results showed a decrease in 5-years all- cause mortality and liver 
related mortality in both groups. [103] However, the current opinion is that the risk 
of HCC may persist up to 10 years after obtaining SVR; the HCV infection appears 
to leave behind an epigenetic scar, inducing carcinogenesis. [104] Therefore, the 
international consensus is that HCC surveillance should continue after antiviral 
therapy, and its duration and periodicity should be based on the general risk of 
HCC of the patient, even deciding on a case to case basis. [105] Besides, the reduc-
tion of HCC risk in patients with decompensated cirrhosis is also controversial, thus 
stimulating further debate regarding the best timing for liver transplantation in 
these patients. [106]
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